Harry & David recall nut-containing candy

Apr 16, 2007

The U.S. Food and Drug Administration announced the recall of approximately 2,000 boxes of candies distributed by the Harry & David Operations Corp.

The recalled candy might contain undeclared nuts, including peanuts, almonds, pecans, walnuts and cashews, thereby posing a health risk for people who are allergic to nuts.

Harry & David is recalling all lot codes of the products that were packaged in 6 oz. paperboard boxes with a folded over top. The candy, packaged with various striped color variations, includes: Dark Chocolate Clusters The Ultimate Walnut Cherry Caramel Indulgence candies in green and cream striped boxes; Dark Chocolate Clusters The Ultimate Peanut & Peanut Butter Indulgence in red and cream striped boxes; Dark Chocolate Clusters The Ultimate Pecan Cranberry Caramel Indulgence in dark red and cream striped boxes; Whole Almond Confection in brown and white striped boxes, and Whole Cashew Confection in dark red and cream striped boxes.

The candies were produced and packaged by a third party vendor and distributed nationwide through Harry and David Stores beginning in March.

Consumers can return the recalled candy for a full refund and can contact the Medford, Ore., company at 800-233-1101.

Copyright 2007 by United Press International

Explore further: 'Beach body' ads investigated after outcry in Britain

Related Stories

Someday, a way to 'see' nuclear, chemical threats

Apr 01, 2010

Ordinarily, the small square of plastic and glass has a reddish color. But when Drexel University graduate student Sameet Shriyan flicks a switch, applying a bit of electricity, suddenly the red fades and the material becomes ...

Recommended for you

Dutch DSM posts Q1 slump

Apr 29, 2015

Dutch pharmaceutical group DSM posted a 70 million euro first quarter net loss Wednesday despite an 11 percent jump in sales, boosted by higher animal nutrition volumes and favourable exchange rates.

New meds help drugmakers weather strong dollar, other issues

Apr 28, 2015

Revenue from important new medicines for various cancers, hepatitis C and more helped top U.S. drugmakers weather unfavorable currency exchange rates and other challenges. Pfizer Inc., Merck & Co. and Bristol-Myers Squibb ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.